Compass Therapeutics, Inc.
Compass Therapeutics, Inc. (CMPX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
cmpx · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Compass Therapeutics, Inc. (CMPX) measures how much investors pay for each dollar of the company's trailing earnings. CMPX's current PE ratio of N/A is calculated by dividing its stock price of $2.03 by its TTM earnings per share of -$0.37.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2019 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Compass Therapeutics, Inc.You CMPX | $281M | N/A | — | -$0.37 |
 Bicycle Therapeutics plc BCYC | $294M | N/A | — | -$3.16 |
 Corvus Pharmaceuticals, Inc. CRVS | $935M | N/A | — | -$0.19 |
 4D Molecular Therapeutics, Inc. FDMT | $444M | N/A | — | -$2.42 |
 Fulcrum Therapeutics, Inc. FULC | $191M | N/A | — | -$1.18 |
 Gossamer Bio, Inc. GOSS | $39M | N/A | — | -$0.75 |
 KalVista Pharmaceuticals, Inc. KALV | $1.4B | N/A | — | -$3.23 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.42 | — | |
2024-12-31 FY2024 | — | $-0.36 | — | |
2023-12-31 FY2023 | — | $-0.33 | — | |
2022-12-31 FY2022 | — | $-0.37 | — | |
2021-12-31 FY2021 | — | $-1.31 | — | |
2020-12-31 FY2020 | — | $-0.52 | — | |
2020-03-31 FY2020 | — | $-0.67 | — | |
2019-03-31 FY2019 | — | $-7.66 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Compass Therapeutics, Inc. (CMPX) measures how much investors pay for each dollar of the company's trailing earnings. CMPX's current PE ratio of N/A is calculated by dividing its stock price of $2.03 by its TTM earnings per share of -$0.37.
Frequently asked questions
CMPX pe ratio · 6 questionsCMPX's current PE ratio is N/A as of 2026-06-08, based on a stock price of $2.03 and TTM EPS of -$0.37. Data sourced from Financial Modeling Prep via CMPX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Compass Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08